AB SCIEX, Genedata & LECO Announce Partnership for New Cross-Platform Metabolomics Data Analysis Solution

01 Jul 2013
Share
AB SCIEX, Genedata, and LECO announce a technology partnership that will deliver a collaborative software system, which will enable metabolomics researchers to comprehensively process and analyze experimental data across different GC/MS and LC/MS platforms.

LECO Corporation, a global leader in accurate mass technologies and GC/MS instrumentation, is offering combined solutions with both AB SCIEX, a global leader in LC/MS technology, and Genedata, a global leader in advanced software solutions for drug discovery and life science research. The companies are collaborating to provide a seamless solution to extract valuable biological information from high fidelity LC and GC data. The solution will give metabolomics researchers the ultimate tool for truly comprehensive metabolomics investigations. The partnership announcement was made at the 9th Annual Conference of the Metabolomics Society (July 1-4).

“The ability to bring data from different vendors and technologies onto a single platform, which can process and merge data for maximum biological inference, is where the industry needs to be to effectively evaluate the entire metabolome,” said Dr. Vladimir V. Tolstikov, Scientist, Tailored Therapeutics of Eli Lilly and Company.

The close collaboration of the three companies has resulted in the latest version of Genedata Expressionist® MSX software, developed for metabolomics experiments performed with LECO and AB SCIEX MS systems. Genedata Expressionist MSX, which is compatible with other data formats and technologies as well, is a comprehensive, end-to-end solution for the analysis of mass spectrometry data generated in metabolomics experiments. The software can be downloaded directly via the Internet for immediate installation.

Request Info


Company website

LECO Corp.
profile photo

Sarah Thomas
Editorial Assistant